Lymphatica Medtech Secures $17.9M in Series B Funding to Advance Revolutionary Lymphedema Treatment Technology

Lymphatica Medtech, a pioneering company dedicated to improving the lives of patients with lymphatic diseases, has successfully raised an impressive $17,900,000 in its latest funding round. Established in 2017 as a spin-off from two leading Swiss universities, Lymphatica has been on the forefront of innovation in the medical device sector. The company's flagship product, LymphoDrain, represents a groundbreaking leap in the treatment of lymphedema—an often-debilitating condition characterized by the swelling of limbs due to lymphatic dysfunction. LymphoDrain works by implanting artificial lymphatic vessels that facilitates the recirculation of lymph fluid within the body, helping to restore the physiological fluid equilibrium in patients. This cutting-edge technology not only aims to enhance the quality of life for individuals suffering from lymphedema but also addresses the broader challenges associated with lymphatic diseases. The funds raised will be utilized to accelerate product development, facilitate clinical trials, and expand the company’s outreach efforts in raising awareness about lymphatic disorders. Lymphatica's commitment to advancing lymphatic therapies positions it as a key player in the medical device industry, with a mission to transform the landscape of lymphatic treatment options and provide hope to countless sufferers of lymphatic diseases. With this latest funding, the company is well-poised to propel its innovative solutions into the market and make a significant impact in the lives of patients worldwide.